Comment aborder la première ligne thérapeutique dans le carcinome rénal à cellules claires métastatique : de la surveillance active aux combinaisons à base d’immunothérapie

Iakovidou, Ilektra;Desimpel, Grégoire;Hoolans, Damien;Gizzi, Marco;Seront, Emmanuel;et.al.
(2024) Louvain médical — Vol. 143, n° 9-10, p. 560-568 (2024)

Files

2024_Iakovidou_560-568.pdf
  • Open Access
  • Adobe PDF
  • 354.26 KB
Download

Details

Authors
Show more
Abstract
(en) First-line treatment in metastatic clear cell renal cell carcinoma: from active surveillance to immunotherapy-based combinations Metastatic clear cell renal cell carcinoma (ccRCC) is a major challenge for clinicians. Although immunotherapy has revolutionized the management of patients with ccRCC, responses remain inconsistent and often transient, ultimately leading to therapeutic resistance. As a result, new strategies have been developed involving novel molecules with innovative mechanisms of action. This review sheds light on the pathogenic mechanisms and the advances in therapeutic strategies for metastatic ccRCC.
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Iakovidou, I., Desimpel, G., Hoolans, D., Gizzi, M., Van Damme, J., Tombal, B., & Seront, E. (2024). Comment aborder la première ligne thérapeutique dans le carcinome rénal à cellules claires métastatique : de la surveillance active aux combinaisons à base d’immunothérapie. Louvain médical, 143(9-10), 560-568. https://hdl.handle.net/2078.5/271450 (Original work published 2024)